Personal information

No personal information available

Biography

Dr. Shi Ming has sufficient experience in liver cancer treatment including locoregional and systemic therapy, like surgery, interventional therapy, target therapy and immunotherapy. He has done a lot of clinical trials and fundamental research focus on optimizing the treatment of stages of B&C HCC. He has numerous publications as corresponding author in the J Clin Oncol, JAMA Oncol, J Natl Cancer Inst, Hepatology, and more. He also figured out that arterial chemotherapy is the critical factor to improve the TACE effect, and proposed a new scheme of hepatic arterial infusion chemotherapy of FOLFOX (FOLFOX-HAIC). Furthermore, he has proposed a new treatment strategy: triple combined therapy (FOLFOX-HAIC + target therapy + immunotherapy) for advanced hepatocellular carcinoma. Additionally, he has done much research to figure out novel biomarkers predicting drug resistance, and discovered a novel therapeutic target of hepatocellular carcinoma. The above research projects have been cited by six international guidelines and consensuses, including the 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights, Guidelines of Chinese society OF clinical oncology (CSCO): Hepatocellular carcinoma, Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO, EASL–EORTC Clinical Practice Guidelines: Management (2012), and Guidelines of the American Society for Interventional Radiology for Liver Cancer (2012).

Activities

Collapse all

Employment (1)

Sun Yat-sen University Cancer Center: Guangzhou, CN

Professor, Chief physician, Doctoral supervisor (Department of Hepatobiliary Oncology)
Employment
Source: Self-asserted source
Ming Shi

Education and qualifications (2)

Sun Yat-sen University Cancer Center: Guangzhou, CN

Professor (Department of Hepatobiliary Oncology)
Qualification
Source: Self-asserted source
Ming Shi

Sun Yat-sen University: Guangzhou, Guangdong, CN

(Sun Yat-sen University Zhongshan School of Medicine)
Education
Source: Self-asserted source
Ming Shi

Professional activities (2)

Sun Yat-sen University Cancer Center: Guangzhou, CN

winner of the National Science Fund for Distinguished Young Scholars
Distinction
Source: Self-asserted source
Ming Shi

Chinese Society of Liver Cancer (CSLC): Shanghai, CN

Membership
Source: Self-asserted source
Ming Shi

Funding (1)

Dubr调控肝癌干性和耐药的机制

Grant
National Natural Science Foundation of China (Beijing, CN)
GRANT_NUMBER:

No.82072610
Source: Self-asserted source
Ming Shi

Works (50 of 52)

Items per page:
Page 1 of 2

UBA2 SUMOylates NQO1 and promotes the proliferation of hepatocellular carcinoma by modulating the MAPK pathway

Cancer Science
2024-09 | Journal article
DOI: 10.1111/cas.16290
Contributors: Hailong Chen; Huifang Li; Minke He; Zhicheng Lai; Lichang Huang; Dongsheng Wen; Ming Shi; Anna Kan
Source: check_circle
Crossref

Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries

Current Opinion in Pharmacology
2023-06 | Journal article
DOI: 10.1016/j.coph.2023.102362
Contributors: MinKe He; ShuYue Liu; ZhiCheng Lai; ZeFeng Du; QiJiong Li; Li Xu; Anna Kan; JianXian Shen; Ming Shi
Source: check_circle
Crossref

A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma

Cancer Cell International
2022-12 | Journal article
DOI: 10.1186/s12935-022-02507-z
Contributors: Xiaoyun Bu; Luyao Ma; Shuang Liu; Dongsheng Wen; Anna Kan; Yujie Xu; Xuanjia Lin; Ming Shi
Source: check_circle
Crossref

Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma

Hepatology Communications
2022-11 | Journal article
DOI: 10.1002/hep4.2079
Contributors: Miran Kim; Kam Man Hui; Ming Shi; Nancy Reau; Costica Aloman
Source: check_circle
Crossref

Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy

Molecular Therapy - Oncolytics
2022-09 | Journal article
DOI: 10.1016/j.omto.2022.07.001
Contributors: Xiaoyun Bu; Shuang Liu; Dongsheng Wen; Anna Kan; Yujie Xu; Xuanjia Lin; Ming Shi
Source: check_circle
Crossref

Reply to J. Mei et al

Journal of Clinical Oncology
2022-06-01 | Journal article
DOI: 10.1200/JCO.22.00020
Contributors: Min-Ke He; Qi-Jiong Li; Zhi-Cheng Lai; Ye-Xing Huang; Ming Shi
Source: check_circle
Crossref

Construction of a single nucleotide variant score-related gene-based prognostic model in hepatocellular carcinoma: analysis of multi-independent databases and validation in vitro

Cancer Cell International
2021-12 | Journal article
DOI: 10.1186/s12935-021-02321-z
Contributors: Yu-Jie Xu; Min-Ke He; Shuang Liu; Li-Chang Huang; Xiao-Yun Bu; Anna Kan; Ming Shi
Source: check_circle
Crossref

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial

Journal of Clinical Oncology
2021-10-14 | Journal article
DOI: 10.1200/jco.21.00608
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Ming Shi

Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin

Therapeutics and Clinical Risk Management
2021-01 | Journal article
DOI: 10.2147/TCRM.S283192
Contributors: Yang Zhao; MinKe He; RunBin Liang; QiJiong Li; Ming Shi
Source: check_circle
Crossref

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

JAMA Oncology
2019-07-01 | Journal article
DOI: 10.1001/jamaoncol.2019.0250
Part of ISSN: 2374-2437
Source: Self-asserted source
Ming Shi

Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy

Cancer Medicine
2018-11 | Journal article
DOI: 10.1002/cam4.1521
Contributors: Hai‐Long Chen; Han‐Yue OuYang; Yong Le; Peng Jiang; Hui Tang; Zi‐Shan Yu; Min‐Ke He; Yun‐Qiang Tang; Ming Shi
Source: check_circle
Crossref

Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis

CardioVascular and Interventional Radiology
2018-05-11 | Journal article
DOI: 10.1007/s00270-017-1874-z
Contributors: Min-Ke He; Ru-Hai Zou; Qi-Jiong Li; Zhong-Guo Zhou; Jing-Xian Shen; Yong-Fa Zhang; Zi-Shan Yu; Li Xu; Ming Shi
Source: check_circle
Crossref

MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma

Hepatology
2016-04 | Journal article
DOI: 10.1002/hep.28397
Part of ISSN: 0270-9139
Source: Self-asserted source
Ming Shi

A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma.

2014-03 | Journal article
DOI:

10.1016/j.ejca.2013.11.026

PMID:

24332572
Contributors: Shi M; Chen MS; Sekar K; Tan CK; Ooi LL; Hui KM
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors.

2013-12 | Journal article
DOI:

10.1007/s12032-013-0696-3

PMID:

23975633
Contributors: Li SH; Wei W; Guo RP; Shi M; Guo ZX; Chen ZY; Xiao CZ; Cai MY; Zheng L
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma.

2013-09 | Journal article
DOI:

10.1158/1078-0432.CCR-12-2728

PMID:

23812667
Contributors: Wei R; Huang GL; Zhang MY; Li BK; Zhang HZ; Shi M; Chen XQ; Huang L; Zhou QM; Jia WH et al.
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.

2013-04 | Journal article
DOI:

10.1111/liv.12112

PMID:

23402625
Contributors: Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X et al.
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Response to Dr Chan et al.

2013-04 | Journal article
DOI:

10.1093/jnci/djt046

PMID:

23724419
Contributors: Luo J; Shi M
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial.

2013-01 | Journal article
DOI:

10.1093/jnci/djs464

PMID:

23150720
Contributors: Shi M; Lu LG; Fang WQ; Guo RP; Chen MS; Li Y; Luo J; Xu L; Zou RH; Lin XJ et al.
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.

2013 | Journal article
DOI:

10.1371/journal.pone.0060444

PMID:

23565248

PMC:

PMC3614950
Contributors: Liao Y; Wang B; Huang ZL; Shi M; Yu XJ; Zheng L; Li S; Li L
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Risk Factors for Early and Late Intrahepatic Recurrence in Patients with Single Hepatocellular Carcinoma Without Macrovascular Invasion after Curative Resection.

2013 | Journal article
PMID:

24083739
Contributors: Li SH; Guo ZX; Xiao CZ; Wei W; Shi M; Chen ZY; Cai MY; Zheng L; Guo RP
Source: Self-asserted source
Ming Shi via Europe PubMed Central

An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma.

2012-08 | Journal article
DOI:

10.1016/j.jhep.2012.03.027

PMID:

22521360
Contributors: Xu J; Ding T; He Q; Yu XJ; Wu WC; Jia WH; Yun JP; Zhang Y; Shi M; Shao CK et al.
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study.

2012-03 | Journal article
DOI:

10.1148/radiol.11110817

PMID:

22357902
Contributors: Peng ZW; Lin XJ; Zhang YJ; Liang HH; Guo RP; Shi M; Chen MS
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Allele loss and down-regulation of heparanase gene are associated with the progression and poor prognosis of hepatocellular carcinoma.

2012 | Journal article
DOI:

10.1371/journal.pone.0044061

PMID:

22952874

PMC:

PMC3432106
Contributors: Huang GL; Li BK; Zhang MY; Wei RR; Yuan YF; Shi M; Chen XQ; Huang L; Zhang HZ; Liu W et al.
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.

2012 | Journal article
DOI:

10.1186/1479-5876-10-245

PMID:

23228017

PMC:

PMC3552726
Contributors: Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma.

2011-06 | Journal article
DOI:

10.1111/j.1872-034X.2011.00796.x

PMID:

21615643
Contributors: Lao XM; Wang D; Shi M; Liu G; Li S; Guo R; Yuan Y; Chen M; Li J; Zhang Y et al.
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.

2011-05 | Journal article
DOI:

10.1016/j.jvir.2010.12.041

PMID:

21514523
Contributors: Huang ZL; Luo J; Chen MS; Li JQ; Shi M
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection.

2011-05 | Journal article
DOI:

10.1111/j.1440-1746.2010.06511.x

PMID:

21488945
Contributors: Chen ZY; Wei W; Guo ZX; Lin JR; Shi M; Guo RP
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis.

2011-04 | Journal article
DOI:

10.1148/radiol.10101072

PMID:

21330557
Contributors: Luo J; Peng ZW; Guo RP; Zhang YQ; Li JQ; Chen MS; Shi M
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study.

2011-02 | Journal article
DOI:

10.1245/s10434-010-1321-8

PMID:

20839057
Contributors: Luo J; Guo RP; Lai EC; Zhang YJ; Lau WY; Chen MS; Shi M
Source: Self-asserted source
Ming Shi via Europe PubMed Central

LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma.

2010-04 | Journal article
DOI:

10.3748/wjg.v16.i16.2046

PMID:

20419844

PMC:

PMC2860084
Contributors: Huang GL; Li BK; Zhang MY; Zhang HZ; Wei RR; Yuan YF; Shi M; Chen XQ; Huang L; Li AH et al.
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China.

2010-01 | Journal article
DOI:

10.3748/wjg.v16.i2.264

PMID:

20066748

PMC:

PMC2806567
Contributors: Shi M; Chen JA; Lin XJ; Guo RP; Yuan YF; Chen MS; Zhang YQ; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration.

2010 | Journal article
DOI:

10.1007/s12072-010-9192-4

PMID:

21063476

PMC:

PMC2940006
Contributors: Chen JA; Shi M; Li JQ; Qian CN
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Correlation of preoperative neutrophil-to-lymphocyte ratio to prognosis of young patients with hepatocellular carcinoma].

2009-11 | Journal article
PMID:

19895743
Contributors: Guo ZX; Wei W; Zhong C; Shi M; Chen MS; Guo RP
Source: Self-asserted source
Ming Shi via Europe PubMed Central

A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.

2009-10 | Journal article
DOI:

10.1007/s00432-009-0588-2

PMID:

19408012
Contributors: Zhong C; Guo RP; Li JQ; Shi M; Wei W; Chen MS; Zhang YQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection.

2009-03 | Journal article
DOI:

10.1016/j.humpath.2008.08.011

PMID:

18992916
Contributors: Ding T; Xu J; Wang F; Shi M; Zhang Y; Li SP; Zheng L
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Effects of cetuximab combined erlotinib on proliferation of human hepatocellular carcinoma cell lines HepG2 and Bel-7402].

2008-04 | Journal article
PMID:

18423125
Contributors: Wei W; Guo RP; Li JQ; Xu L; Shi M; Zhang YQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Efficacy of pulmonary resection for primary hepatocellular carcinoma patients with pulmonary metastasis].

2008-03 | Journal article
PMID:

18334126
Contributors: Liang WC; Guo RP; Chen MS; Long H; Shi M; Wei W; Zhang YQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Correlation of perioperative alpha-fetoprotein expression in peripheral blood to recurrence of hepatocellular carcinoma].

2008-01 | Journal article
PMID:

18184471
Contributors: Shi M; Zhang Y; Zhong C; Lin XJ; Zhang CQ; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial.

2007-01 | Journal article
DOI:

10.1097/01.sla.0000231758.07868.71

PMID:

17197963
Contributors: Shi M; Guo RP; Lin XJ; Zhang YQ; Chen MS; Zhang CQ; Lau WY; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Expression and clinical significance of certain apoptosis and angiogenesis factors in hepatocellular carcinoma].

2006-12 | Journal article
PMID:

17359695
Contributors: Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[The value of TissueLink hemostatic sealer in hepatectomy for hepatocellular carcinoma].

2006-11 | Journal article
PMID:

17094918
Contributors: Wei W; Guo RP; Shi M; Zhong C; Yu WS; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Expression of CXCR3 in hepatocellular carcinoma].

2006-10 | Journal article
PMID:

17059766
Contributors: Shi M; Guo RP; Zhang CQ; Zhong C; Lin XJ; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

2006-09 | Journal article
DOI:

10.1007/s00432-006-0097-5

PMID:

16763805
Contributors: Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma].

2006-07 | Journal article
PMID:

16831281
Contributors: Cui BK; Zhang CQ; Zhang Y; Yuan YF; Zhang YQ; Shi M; Chen MS; Li SP; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Expression and clinical significance of VEGF and MMP-9 in hepatocellular carcinoma].

2006-05 | Journal article
PMID:

16687082
Contributors: Zhong C; Guo RP; Shi M; Wei W; Yu WS; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Expression and clinical impact of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma].

2006-04 | Journal article
PMID:

16875630
Contributors: Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Influence of surgical resection margin in hepatectomy on survival of patients with hepatocellular carcinoma].

2006-01 | Journal article
PMID:

16737621
Contributors: Xu L; Shi M; Zhang YQ; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Evaluation of new TNM staging system for hepatocellular carcinoma after hepatectomy].

2005-07 | Journal article
PMID:

16004798
Contributors: Li BK; Cui BK; Yuan YF; Li JQ; Zhang YQ; Shi M; Li GH
Source: Self-asserted source
Ming Shi via Europe PubMed Central

[Prophylaxis and clinical treatment for surgical margin recurrence of small primary hepatocellular carcinoma].

2005-07 | Journal article
PMID:

16004810
Contributors: Fang WQ; Li SP; Zhang CQ; Xu L; Shi M; Chen MS; Li JQ
Source: Self-asserted source
Ming Shi via Europe PubMed Central
Items per page:
Page 1 of 2

Peer review (1 review for 1 publication/grant)

Review activity for European radiology. (1)
How many people are using ORCID?